ABSTRACT Diabetes mellitus is a disease of major global importance, increasing in frequency at almost epidemic rates. In order to optimize diabetes management and, therefore, reduce hyper-or hypo-glycaemia complications, continuous and reliable in vivo (subcutaneous or intravenous) glucose monitoring is indispensable. To that end, subcutaneous sensors have progressed more rapidly as they can be linked to state-of-the-art signal transmission modes (transdermal, IR, etc.). Yet, most of the devices currently at clinical trials have not demonstrated a stable and clinically useful sensor performance. In this work, the causes of subcutaneous glucose biosensor sensitivity drift have been investigated by means of fault tree analysis relying on fuzzy reasoning to account for uncertainty. Using the methodology proposed herein, all ultimate causes or combination of causes attributed to the device components, the surrounding tissue and their intra/inter-relations that are responsible for or contribute to the top event have been recognized and quantifi ed based on (a) measurements for the deterministic contributors and (b) experience for the stochastic contributors. The tree structure has been designed by combining deduction and induction, top-down and bottom-up techniques, thus establishing a dialectic tradeoff which brings this method closer to scientifi c logic, permitting the introduction of deeper knowledge into the surface or experiential knowledge level characterizing FTA. The proposed methodology has been implemented in the investigation of the causes responsible for sensor fouling by thrombus formation and has proven to be an effi cient tool for internal diagnostics and fault compensation. The suggested approach may contribute signifi cantly to the self-optimization of the measuring equipment from one generation to the next as it supports the fl exible, ad hoc, and tailor-made development, thus potentiating the progress of epidemics from statistics to individualization.
INTRODUCTION
Glucose is a major source of energy for cells, and it is transported to cells via insulin in the blood stream. The human body regulates blood glucose at a concentration range of 4-8 mM (70-120 mg/dL); in the presence of physiopathological conditions, the range can extend to 2-30 mM (30-500 mg/dL). Diabetes is a metabolic disease, resulting in abnormal blood glucose levels and, consequently, in the activation of several metabolic pathways related to infl ammation and apoptosis events [1] . Long-term adverse effects of glucose deregulation have been well documented, representing a leading cause of mortality and several complications to retina, circulatory system and kidneys. According to Shaw et al. [2] , the world incidence of diabetics was 6.4% in 2010, expected to rise to 7.7% by 2030.
To manage diabetes and, therefore, reduce hyper-or hypo-glycaemic complications, much research effort and funding are devoted to the development of smart diagnostic tools [3, 4] . Accurate and systematic glucose monitoring is a key element for allowing patients to keep their glucose levels under control and for providing physicians with a more accurate and detailed picture of the disease. The available self-monitoring devices based on discrete measurements, apart from causing patients' discomfort, do not allow an overall, clear and in-depth view of the actual glycaemic status, especially in type I diabetics, where glycaemia may undergo rapid changes [5, 6] . Continuous in vivo glucose monitoring would improve diabetic control, especially in less-apt individuals (young, elderly, mentally challenged, etc.) [6] . It could also provide valuable information to R&D regarding in vivo kinetic parameters after lunch, during sleep or exercise, etc.; this could be the fi rst step towards a completely closed-loop control system that automatically monitors and maintains euglycaemia (artifi cial pancreas) [7] .
Numerous implantable miniaturized sensors are being developed, mostly on the electroenzymatic approach [5, 6] ; based on polarographic principles, these devices utilize the oxidation of glucose by glucose oxidase and measure amperometrically or potentiometrically the reduction of the produced hydrogen peroxide (Fig. 1 ). Implantable sensors have been thus far plagued to various degrees and extents by problems of prolonged lag between blood and interstitial fl uid glucose levels during dynamic glucose fl uctuations, inadequate accuracy, safety concerns, and/or poor portability [8] . Only subcutaneous sensors have reached a suffi cient level of performance for several products during clinical trials, mainly from Medtronic Diabetes, Abbot, and Dexcom [9] .
For subcutaneous operation, the sensors are designed with standard integrated circuit microfabrication processes; all signal processing can be accomplished on-board the chip, and the entire package is not more than a few square millimetres in size (Fig. 1) ; the signal is transmitted to an ex vivo recorder by state-of-the-art modes (transdermal, IR, etc.). Unfortunately, the response of these devices undergoes a signifi cant decrease when exposed to in vivo biological environment, attributed vastly to biocompatibility issues (infl ammation, fi brosis, scar formation, clot formation in blood vessels, other tissue reactions [10, 11] ), and biofouling (excessive protein deposition clogging the sensor's membrane pores with proteins resulting in a decrease or cessation of the fl ow of molecules to the sensor [12] [13] [14] ), although sensor corrosion [15, 16] , along with the inherent sensor pitfalls (mainly problems associated with the biorecognition/transducer interface [16] ) have been frequently reported. Nonetheless, the clinical trials made apparent that the in vivo performance of the sensors differs signifi cantly than the ex vivo one, making calibration diffi cult, usually expressed as a rapid and signifi cant sensor drift [17, 18] ; current research is focused towards automatic calibration upon insertion, a procedure that could potentially ensure the accuracy of the sensor's data output.
In view of (i) the inter-disciplinary and diverse nature of the subject, involving a merging between the fi elds of biochemistry, engineering, human physiology, and electronics, (ii) the complexity presented by the specifi c application, and (iii) the severity of the application, these devices require, inevitably, an intelligent system for real-time fault detection and, preferably, fault compensation, as well, an area that has not received yet much attention. The real-time response of such a system is imperative when considering that misleading glucose readings may result in inappropriate drug delivery that could stimulate vicious feedback cycles, threatening the life of the patient (e.g. severe hypoglycaemic episodes) [1, 8] . The identifi cation of the possible sensor fault modes and their symptoms is a prerequisite for constructing such a system, requiring in-depth knowledge of sensor's design and operation, both from the electrochemical and the physiological/biochemical point of view. The most usual and critical fault mode in subcutaneous biosensors is sensitivity drift, which results to either an inaccurate measurement or a dead sensor [16] . The environment within which the sensor operates, involving complex multi-component chemical interactions and exhibiting intricate multi-phase microstructures, increases uncertainty manifold, since there could be (and usually are) many infl uences acting simultaneously or consecutively, masking, partially or totally, the identifi cation of the problem source. However, diagnosis usually depends on symptomatology and not on aetiology, i.e. the actual measurement of the variables/parameters associated with the problem (online or offl ine); thus, any misfunction may be realized when its impact becomes critical and not when it arises, making online rectifi cation impossible, at least at a degree that could ensure both patient's well being and sensor functionality.
There have been several attempts for understanding the possible failure mechanisms responsible for the poor in vivo performance of subcutaneous sensors, but still there is no clinical concept available and more insight is required in the physiological processes at the sensor-tissue interface. Limited information and high uncertainty has been successfully handled in certain biomedical cases with fuzzy logic [19, 20] . Fuzzy sets theory provides a way to use imprecise and uncertain information generated by the environmental system and the human judgement in a satisfactory way, in cases where absolute criteria should be avoided and the intuitive aspects of the experts' judgment should be preserved [16, [21] [22] [23] . The work presented herein investigates the causes of subcutaneous biosensor sensitivity reduction by means of fault tree analysis (FTA), using the information provided by the biosensor components, the surrounding tissue, and their intra/inter-relations on both the surface-and the deep-knowledge level, simulating an expert system, where the tree (dendritic) structure (with the corresponding to each node appropriate confi rmation tests and remedial proposals/advices) serves as the Knowledge Base (KB) and the fuzzy rules based decision mechanism on aetiology is the inference engine.
METHODOLOGY
The methodology developed by the authors relies mainly on the design/development of a hierarchical structure capable of performing FTA within a framework incorporating (a) the trunk of the SNR-decrease fault tree (i.e. the content part of the fault analysis) and (b) a mechanism of (i) assigning fuzzy partition of the space of the variables represented by each tree node and (ii) setting/ revising of fuzzy rules used as an inference engine (i.e. the formal part of fault analysis).
The formal algorithmic part
The algorithmic procedure especially designed and implemented for computer-aided subcutaneous biosensor fault diagnosis includes 20 activity stages and 7 decision nodes, as described below; for their interconnection, see 5. Collection of information concerning other variables/parameters/constraints related to the nodes of the tree. 6. Confi rmation of the tree structure (content and architecture) by induction. 7. Extension of the tree and its scientifi c basis. 8. Fuzzy partitioning of the space of the variables representing each node of the tree. 9. Determination of the fuzzy rules. 10. Estimation of a threshold (maximum tolerable) value, T, for the top event. 11. Listing of (remaining) combinations of fi nal events that may produce the top event; ranking of them according to decreasing infl uence on the top event. 12. Listing of combinations (constituting the antecedent or IF-part) of fuzzy rules that belong to the same combination of fi nal events; ranking of them according to decreasing infl uence on the top event. 13. Running of the fuzzy FTA bottom-up algorithm for the combinations suggested in stage 12 to fi nd out the top event value as a crisp number (after defuzzifi cation). 14. Reforming of the fuzzy rules, where necessary. The tree is structured in a top-down direction by deduction (stage 4), involving the identifi cation of the events or series of events that directly contribute to the top event, the immediate causes of these events and so forth, until the ultimate or fi nal causes are identifi ed. Conversely, a revision can be made by induction (stage 7), after proper information has been collected (stage 5). This dialectic trade-off between deduction and induction brings the tree design closer to scientifi c logic, permitting the introduction of deeper knowledge into the surface or experiential knowledge level characterizing FTA.
Once the fi nal form (in content and architecture) of the fault tree has been agreed upon (stage 6), the partitioning of the space of variables and the determination of the fuzzy rules serving as an inference engine for diagnosis (stages 8 and 9) can been achieved by using experts' opinion through a modifi ed four-stage Delphi method. Running the fuzzy FTA bottom-up (stage 13), using fi rst the combination of the fi nal events that contributes mostly (as per strength and frequency) to the top event, a crisp number is calculated for the latter and compared with the specifi ed threshold (stage 10). Similarly, based on a nested loop mechanism described by the decision nodes C and D, the most infl uential combination responsible for the top event is experimentally confi rmed (stage 17) and, if possible, rectifi ed; otherwise, the next combination is examined (stage 11), and so on until the value of the top event reaches the threshold. The selectivity of research is thereby enhanced considerably by concentrating attention to the most infl uential variables, consequently saving resources and increasing research value. In case of a satisfactory remediation, the device, re-engineered at stage 18, is forwarded to clinical testing (stage 19).
The internal KB (stage 20) is the backbone of the procedure and has been developed to support case-based or model-based or rules-based reasoning to facilitate device (re-) engineering and serve online fault diagnostics. Such an integration will effectively assist sensor design to assure the successful development of the fi nal product according to predetermined specifi cations. The formalism adopted herein is quite fl exible to allow for handling a wide range of different cases within this complex and dynamic science-based sector.
The content/trunk-tree part
Sensor sensitivity is a controversial term. It usually implies the slope of the calibration curve in the vicinity of the expected real measurement, a function of analyte concentration or amount [24, 25] ; as such it can be defi ned as either the minimum input signal required to produce a specifi c output, given a certain signal-to-noise ratio, or as the ratio of the signal output for a given concentration to the signal obtained for an adjacent concentration value (C ± 1). This property is very crucial, especially towards the limit of detection, where hypoglycaemic episodes should be identifi ed as soon as possible in order for the patient to receive treatment, as well as for the identifi cation/location of abrupt glucose changes.
In view of the above, the reduction in sensitivity involves either a responsivity decrease, i.e. a decrease of the output signal in response to input [16] , a modifi cation of the analyte fl ux kinetics (the pumping of glucose from the interstitial fl uid in the sensor) [26] , or incorrect calibration, especially in in vivo/ex vivo correlation of glucose levels [17, 18] . The intermediate events that lead to these second-level events can be located when considering the design, the operation, and the environment of the sensor. The basic biosensor detection scheme implies that a working mode requires [21] [22] [23] [24] [25] : (a) the analyte to be able to enter the reaction chamber, via favourite diffusion kinetics, whereas the interferents must be excluded based on diffusion limitations and (b) the analyte entering the reaction chamber must be able to reach the bioreceptor and, under favourite conditions, must be strong enough to enhance proper biomaterial orientation and prevent leakage, yet to react with it; (c) the biomaterial, apart from being specifi c to the analyte, must retain its full functionality, in order for the reaction to yield the product; (d) the biomaterial/support interactions support must not interact with the functional groups of the biomaterial nor alter its physicochemical state; (e) the reaction product or any by-product must not poison the biomaterial or the support; (f) the product must be effectively transferred to the transducer without scattering, either by crossing the support of via mediators; (g) the transducer shows no drift (e.g. polarized electrode) or fouling; and (h) the analyte or the product is washed off and the functional biomaterial sites are regenerated. Any misfunction of the above is considered critical and can lead to a noisy biosensor, or an inaccurate signal output [16] , i.e. each step of biosensing contributes to possible fault generation and its propagation to the secondlevel events (1.1, 1.2, and 1.3). Figure 3 : The upper part of the fault tree investigating the causes of sensitivity drift in subcutaneous sensors: the qualitative upper part of the tree constituting the content part of the methodological framework (the formal being the mechanism of setting/revising the fuzzy rules).
Fuzzy partition of the space of the variables
Each tree node has been quantifi ed using ranges of values that could be described by the linguistic terms (fuzzy sets) low, medium, and high. The degree, or weighting, with which any value belongs to a fuzzy set is represented by the membership function; over their domain of interest/validity, the membership functions take a value between 0 and 1; each term is schematically presented as a triangle, peaking at the value that the node-event is most commonly found (membership function 1). The overlapping of the space of variables depends on the uncertainty of the measure or effect of the event.
Working in the bottom-up mode within the tree-like structure, the quantifi cation of each node depends on its direct sub-ordinates, considering (a) their value and (b) the degree of their contribution to the node. This relation is given by a series of fuzzy rules that determine the output of the node as fuzzy set. The basal events (ultimate causes) are entered as fuzzy numbers or as crisp values and their fuzzy output enters subsequently the direct upward intermediate event/node, which is thus quantifi ed, and so forth until a fuzzy number produced for quantifying the top event; after defuzzifi cation, a crisp value is obtained to serve as a more meaningful term in common vocabulary. Similarly, all fuzzy numbers produced by the inference engine and assigned to each intermediate event may appear as crisp values, to illustrate the fault infl uence/propagation along the corresponding path.
3 IMPLEMENTATION AND RESULTS The methodology described above has been implemented in node 1.2.1.1.2.2, 'thrombus formation on the sensor surface' (branch A of Fig. 3) , one of the most commonly encountered problem in implanted materials [12, 13] : the thrombus covers the sensor surface inhibiting glucose diffusion. Following stages 3 and 5 of the algorithmic procedure (Fig. 2) , an extensive literature search provided various causes for this event. The reactions of the body to an implant crucially depends on the surface of the implant [27] , especially the chemical situation present at the surface [13] , the surface texture [27] , the local fl ow conditions [26] , as well as other factors. An extract of the relevant tree is presented in Fig. 4 (stage 4) . It is generally agreed that the 'increased platelet adhesion, activation and aggregation' (node A2.1.1) on implant surfaces exposed precede the formation of the thrombus [28] . Therefore, in vitro analysis of these properties is usually performed as a fi rst test of the haemocompatibility of a surface. Additionally, the platelet morphology (circularity and area) can be taken as an indication of the ability of the surface to support thrombus formation. A high ratio of the proteins albumin/fi brinogen, adsorbed on an implant surface prior to cell or platelet attachment, can be correlated with a low number of adhering platelets and therefore with low tendency of thrombus formation [28] . However, some materials may show contradicting results when implanted, as shown for polyurethane and parylene [29] .
Despite, however, the directly related physiological reasons that contribute to the top even, implant failure can be triggered by seemingly unrelated reasons that necessitated the extension of the tree (stage 7). For example, 'increased calcium' (node A2. [35] , not to mention the high incidence of thyroid hormone-related diseases worldwide (node A2.1.2.1.2.1.2.1.2.2.2.2) [36] , both of which potentially lead to pathogenic hypercalcaemia.
A sample of the fuzzy rules used (stage 9), representing a chain leading from the 18-digit fi nal event A2.1.2.1.2.1.2.1.2.2.1.1 to the 6-digit intermediate event A, used herein as pseudo-top event for inference (the highlighted part of Fig. 4 The threshold value, T, set for the 'top event' (stage 10) is 20%, as proven suitable for retaining much of sensor's functionality. The problem investigated refers mainly to the effect of calcium intake by the subject upon the sensor performance, considering, also, other parallel physiological processes (stage 13). Nine scenarios have been tested (Table 2) aiming at examining all possible combinations and infl uences (the highlighted part of Fig. 4) . The results have shown that at any value of the basal event (cases 1-3), the top event is well below the tolerance value, provided that all other inputs are kept low. There is a slight increase in the top event-value when the 'calcium stores are activated' (node A2.1.2.1.2.1.2.1.2) (case 4), as well as, at 'increased lipid infi ltration' (node A2.1.2.1.2.1.2.2) (case 5), mainly due to 'high cholesterol levels' (node A2.1.2.1.2.1.2.2.1.1). The effect of high blood cholesterol is as signifi cant as expected, since it has been often accused for inducing ex vivo sensor fouling [37] . The latter (cases 6-8), even at medium values can induce the vast formation of thrombus on the sensor surface [6] , resulting at values above the set threshold. It can be thus concluded that after implantation, the cholesterol and histamine blood levels should be carefully monitored at a regular basis to prevent thrombogenic activity. Case 9 examines the possibility that all inputs assume medium values, a situation common at elder patients suffering from the long-term disease complications, where the value of the top event is well above threshold (Fig. 5) . It thus appears that subcutaneous sensors could not be used in this group, unless maintained under intensive drug therapy, a prospect that may not be always possible or could not improve the life quality of these patients. R&D efforts should be, therefore, focused at improving the anti-thrombogenic properties of the sensor's surface, employing new coating materials, to reduce adverse effects.
Working similarly, the results of this study have been classifi ed to short-and medium-term implications of sensor implants. The medium-term problems involve: (a) technological drawbacks, especially on the rate transmission of the biochemical information to the transduction system (lower event of node 1.3.1 in Fig. 3) ; current research on nanotechnology platforms is expected to solve miscommunication issues and lag times [38, 39] ; (b) sample matrix effects, especially related to signal accuracy due to cholesterol levels (node A2.1.2.1.2.1.2.2.1 in Fig. 4 ), haematocrit variations, hyperbaric conditions, and some dialysis drugs such as icodextrin (lower events not shown linked to node 1.2.2.4 in Fig. 3 ); these problems have been also identifi ed in ex vivo testing and could be dealt with correction algorithms and multi-sensing [40] ; (c) poor in vivo/in vitro correlation (node 1.3 in Fig. 3) ; current approaches focus on in vivo calibration and the use of suitable reference matrix materials for ex vivo analytical development [18] ; (d) responsivity problems (node 1.1) related to oxygen tension variability, especially due to decreased blood volume (lower event not shown linked to node 1.1.1.1 in Fig. 3 ) resulting either from microhaemorrhages or from a concurrent infection; enzyme degradation (node 1.1.2) is, also, a signifi cant contributor to the top event, especially when linked to radical attack as a result of low anti-oxidant activity; the employment of microperfusion techniques is expected to improve performance [41] .
Regarding the short-term problems, infl ammation and thrombus formation (nodes 1. Fig. 3 ) have been highlighted as the major contributors. Both are known and expected; they are system disturbance errors, i.e. the sensor disturbs the environment in which it operates, and probably the best way to deal with them is by engineering the device to release anti-infl ammatory chemicals such as nitric oxide [42] . Notwithstanding, the inference engine revealed that there exist some underlying conditions, common in diabetics, that may speed up, enhance, or extend these reactions. Infl ammation has been linked to vasoconstriction due to training, dehydration, or increased supplement intake (especially calcium), whereas thrombus formation is enhanced by anxiety treatment, asthma drugs, and various hormonal problems. These results imply that any drugs included in the device should be decided on an individual basis, and their effi cacy should be closely monitored.
DISCUSSION
The results presented refer to the identifi cation and investigation of the factors (external and/or inherent to biosensing) that alone or in synergy cause sensitivity decrease, in a way that uncertainty of measurement or rectifi cation of performance can be considered more effi ciently and less costly. The incorporation of fuzzy logic in the presented framework facilitates the decision making in R&D with limited information under high uncertainty. Such a tool can effectively serve its purpose in focusing research towards solving or preventing signifi cant problems, until more information is available from clinical trials of the devices or basic biochemical research. As the KB (stage 20 of the algorithmic procedure in Fig. 3 ) is continually enriched, fuzzy rules are revised, narrowing overlapping and increasing the accuracy and reliability of the results. It is worthwhile noting that current knowledge stored in the KB includes many hypothetical or understudied cellular and biochemical mechanisms that should be further elucidated to reduce uncertainty; for example, the primary role of calcium on the modulation of pyruvate dehydrogenase (PDH) phosphorylation could either mediate translocation of the phosphatase to the E2 component of PDH complex [26] or diminishes ATP production by lowering inner membrane voltage [30] ; the fault tree supports both branches, activating the one that each time is proven more intense or dominant. Moreover, the methodology proposed can help in the knowledge elucidation of the clinical aspects of the disease, especially at issues of debate. For example, when sensor misfunctioning is found (after appropriate testing) to be caused by 'thrombus formation on the sensor surface' (node A) which is in turn attributed to 'decreased release of nitric oxide' (lower event not shown linked to node A1.3 in Fig. 4) , the cause of the latter should be identifi ed to apply the appropriate remedies; NO synthesis is inhibited by two possible disjunctive pathways, either the activation of the polyol cycle [41] or the impairment of iron regulation [42] . The clarifi cation of the mechanisms that regulate this interaction is, on one hand, essential to fault compensation, and on the other hand, it may contribute signifi cantly to the improvement of diabetes management and its possible complications.
CONCLUSIONS
The method presented herein serves effectively to localize the causes of sensor drift in subcutaneous biosensors under conditions of uncertainty. When coupled to fuzzy reasoning, it provides a suitable platform for developing online sensor diagnostics and fault compensation. The development and maintenance of a KB facilitates a multi-faceted applicability of the proposed tool. For example, it enhances selectivity of R&D effort by concentrating attention to the most infl uential variables, thus enabling the distinction between critical and non-critical errors. Although the results provided cannot be fully validated under real-operation, they do hold a signifi cant predictive value. Most importantly, this work has highlighted a shifting in sensor design protocols towards ad hoc customised sensor development, thus potentiating the progress of epidemics from statistics to individualization.
